In addition, a gene set enrichment analysis (GSEA) indicated that SLC35A2 is a key E2F target, a transcription factor involved in several types of cancer, including pancreatic adenocarcinoma [72] and hepatocellular carcinoma [73], as well as expressing the immune-related impact on ER+/HER2− BRCA [74]. The gene discussed is SLC35A2; the disease is pancreatic adenocarcinoma.